TIGIT ligands on the surface of tumor-infiltrating CD8+T cells or Tregs can bind to PVR receptors of tumor cells or dendritic cells, promote the production of anti-inflammatory cytokines such as IL-10 and inhibit the immune response. The gene discussed is TIGIT; the disease is neoplasm.